What single-cell sequencing actually measures — and why it matters

Single-cell sequencing (SCS) encompasses methods for isolating, barcoding, amplifying, and sequencing nucleic acids from individual cells in a high-throughput manner — enabling genomic, transcriptomic, epigenomic, and multi-omic characterization at the resolution of a single cell rather than a bulk population. Where conventional sequencing averages molecular signals across thousands of cells and erases biological heterogeneity, SCS preserves it, making the technology indispensable for mapping tumor microenvironments, resolving immune cell clonotypes, and tracing developmental trajectories. The technology has matured from proof-of-concept demonstrations into commercial platforms now deployed across oncology, immunology, developmental biology, and microbiology.

Within the patent dataset analysed here, the technology subdivides into five distinct domains: single-cell RNA sequencing (scRNA-seq) using microfluidic droplet encapsulation and unique molecular identifiers (UMIs); single-cell multi-omics combining genome and transcriptome measurement; single-cell whole-genome sequencing (scWGS) via emulsion-based liquid-phase encoding; immune repertoire sequencing capturing paired TCR/BCR sequences alongside transcriptomes; and computational and database infrastructure for clustering, trajectory inference, and AI-driven cell-type classification. Across all retrieved results, the 10x Genomics Chromium platform is repeatedly cited as the dominant commercial reference point, with multiple filings describing improvements upon or alternatives to its droplet-based microfluidic architecture.

According to the National Human Genome Research Institute, the cost of sequencing a human genome has fallen by multiple orders of magnitude since the completion of the Human Genome Project — a trajectory that has directly enabled the high-throughput, per-cell economics that make commercial SCS platforms viable. The downstream result is a technology landscape where IP strategy must now span wet-lab protocols, library preparation chemistry, platform-level microfluidics, and bioinformatics algorithms simultaneously.

From foundational NGS to multi-omic integration: the innovation timeline

Publication dates in this dataset span from 2010 to early 2026, revealing a field in active mid-to-late growth stage — with the majority of SCS-specific filings concentrated after 2022, consistent with a technology in accelerating commercial deployment rather than early-stage exploration. Three distinct phases characterise the trajectory.

The foundational period (2010–2017) established the technical substrate. Early next-generation sequencing platform literature from the Human Genetics Center, University of Texas (2010), laid the groundwork, while Illumina Cambridge Limited’s 2017 Japanese patent on monoclonal nucleic acid cluster amplification in microarrays reflects the library preparation infrastructure that underpins all downstream SCS workflows.

During the commercial scaling phase (2018–2022), filings from AbVitro LLC (ES, 2022) on high-throughput polynucleotide library sequencing and immune repertoire characterization, and from Regeneron Pharmaceuticals (WO, 2021; MX, 2022; KR, 2022) on bulk and spatial transcriptome deconvolution using scRNA-seq references, indicate heavy institutional investment in applying SCS data computationally. The 10x Genomics Chromium system became the dominant commercial reference during this period, cited across multiple competing filings.

The advanced integration phase (2023–2026) is characterised by a push toward multi-omic integration, third-generation long-read sequencing at the single-cell level, and AI-driven analysis. Key examples include Bioland Laboratory’s scGTP (CN, 2023), Zhejiang University’s dual-penetrating microwell chip (CN, 2024), Southeast University’s liquid-phase whole-genome barcoding (CN, 2024), Sun Yat-sen University’s OmicVerse platform (CN, 2024), and Shanghai Jiao Tong University’s pseudotime and velocity field inference method (CN, 2026).

“The majority of SCS-specific filings in this dataset are concentrated after 2022 — consistent with a technology in accelerating commercial deployment rather than early-stage exploration.”

Four technical clusters shaping the current patent landscape

Patent analysis within this dataset reveals four distinct technical clusters, each addressing a different layer of the single-cell sequencing stack — from cell isolation and library preparation through to computational analysis and clinical application. Understanding these clusters is essential for freedom-to-operate assessments and white-space identification.

Cluster 1: Droplet microfluidic barcoding (transcriptomics-focused)

The dominant commercial paradigm encapsulates individual cells in aqueous droplets within an oil emulsion alongside barcoded beads. Each bead carries a cell barcode and UMI, enabling demultiplexed single-cell transcriptome reconstruction after bulk sequencing. Beijing Quanpu Medical Testing Laboratory’s 2023 CN filing describes an improved mRNA capture workflow explicitly compatible with both 10x Genomics and MGI sequencing platforms — directly addressing the compatibility gap between commercial systems. Zhejiang University’s 2024 CN filing proposes a dual-penetrating microwell chip architecture for in situ nucleic acid labeling and multi-omic library construction, enabling higher throughput by controlling single-cell occupancy more precisely than droplet-based approaches.

Cluster 2: Multi-omic single-cell sequencing (genome + transcriptome)

A growing cluster targets simultaneous measurement of two or more molecular layers from the same cell — linking genotype to phenotype at single-cell resolution. Bioland Laboratory’s scGTP method (CN, 2023) combines Smart-seq2 cytoplasmic transcriptome profiling with SMOOTH-seq nuclear genome analysis on a third-generation Nanopore platform, enabling simultaneous detection of extrachromosomal circular DNA (ecDNA), structural variants (SVs), and alternative splicing in cancer samples. Maihe Biotechnology’s 2023 CN filing uses microfluidic droplets to capture both antibody variable-region sequences and 3′-end barcoded transcriptomes from the same single B cell, using overlap PCR to bridge the antibody constant-region gap that prevents conventional short-read coverage. BitBiome Co., Ltd.’s 2025 JP filing describes a combined workflow performing metagenome analysis and single-cell genome analysis on the same microbial population, with cross-validation and chimera removal to produce improved assembled genome sequences.

Cluster 3: Large-scale whole-genome barcoding and library preparation

A distinct technical cluster addresses whole-genome — rather than transcriptome — coverage at the single-cell level, where the absence of high-copy-number RNA targets presents unique library construction challenges. Southeast University’s 2024 CN filing proposes emulsion-based parallel isolation of individual cell genomes without solid-phase beads, completing transposition, end-repair, and initial amplification within bead-free droplets before demulsification and sequencing library pooling. Menarini Silicon Biosystems’ 2021 JP filing covers deterministic restriction-site whole-genome amplification (DRS-WGA) library generation with dual barcoding adapters, specifically targeting single-cell WGS from circulating tumor cells.

Cluster 4: Computational analysis platforms for single-cell data

An emerging cluster addresses the downstream informatics challenge — clustering, deconvolution, trajectory inference, and AI-driven cell-type classification — as distinct innovations separate from wet-lab protocols. Gwangju Institute of Science and Technology (GIST)’s 2026 KR filing describes a neural-network-based platform for clustering and visualizing single-cell biological information, automatically determining cell types and identifying similar single cells via coordinate-space visualization. Sun Yat-sen University’s OmicVerse-based system (CN, 2024) integrates batch RNA-seq deconvolution, single-cell imputation, and multi-omics analysis in a unified Python-based pipeline, specifically addressing the “interrupted cell” problem in trajectory analysis. Shanghai Jiao Tong University’s 2026 CN filing uses piecewise ordinary differential equations with expectation-maximization optimization to simultaneously reconstruct RNA velocity fields, pseudotime trajectories, and gene regulatory interaction matrices from scRNA-seq data. Regeneron Pharmaceuticals’ WO filing (2021) claims methods for deconvolving bulk or spatial RNA-seq data into cell-type compositions using scRNA-seq-derived reference profiles — a computational bridge between single-cell and population-level sequencing.

Geographic and assignee concentration: China leads, long-read IP is open

China is the dominant jurisdiction for single-cell sequencing patent filings, with at least 10 directly SCS-relevant filings from 2022–2026 spanning wet-lab methods, computational platforms, and application-specific studies. Chinese academic and industrial assignees account for the largest share of recent SCS-specific filings in this dataset, with innovation concentrated across the full stack from library preparation to trajectory analysis. Japan is the secondary hub, with filings largely representing PCT or foreign national phase entries from Western companies rather than Japanese-origin inventions. South Korea is active in computational and database tools, while US and WO entries are represented primarily through Regeneron Pharmaceuticals, AbVitro, and iRepertoire.

The following table summarises the key assignees with SCS-relevant filings in this dataset, their jurisdiction, and focus area:

R&D teams entering this space should monitor CN patent filings as primary leading indicators of SCS innovation. According to WIPO‘s global IP data, China has consistently ranked among the top patent-filing jurisdictions for biotechnology and genomics over recent years — a trend clearly reflected in this single-cell sequencing dataset. The PatSnap Life Sciences intelligence platform enables teams to monitor CN filings in real time alongside global patent families.

Emerging directions and strategic white spaces for IP teams

Based on filings dated 2023–2026 within this dataset, five forward-looking innovation vectors are apparent — each with distinct implications for IP strategy, freedom-to-operate assessment, and R&D investment decisions.

1. Third-generation (long-read) single-cell sequencing

The integration of Nanopore (Oxford Nanopore Technologies) and PacBio long-read platforms into single-cell workflows is an active frontier. Long reads overcome the 300–500 bp limitation of Illumina platforms that prevents full-length transcript and antibody variable-region sequencing. The scGTP filing from Bioland Laboratory (CN, 2023) demonstrates detection of ecDNA and complex structural variants that are invisible to short-read scRNA-seq. BitBiome’s single-cell plus metagenome integration (JP, 2025) similarly leverages long-read assembly. Critically, within this dataset only one filing — Bioland Laboratory’s scGTP — comprehensively addresses Nanopore-based single-cell multi-omics, indicating that the competitive landscape for long-read SCS IP remains relatively open compared to short-read workflows. This represents a white-space opportunity for IP-aware R&D teams.

2. Bead-free and solid-phase-free whole-genome barcoding

Southeast University’s liquid-phase barcoding method (CN, 2024) explicitly eliminates solid-phase beads from the droplet encapsulation step, addressing scalability and cost barriers in single-cell whole-genome sequencing that do not apply to transcriptome methods. This approach completes transposition, end-repair, and initial amplification within bead-free droplets before demulsification and sequencing library pooling — a workflow distinction that may carry significant IP separation from existing bead-dependent platforms.

3. AI and neural network integration into single-cell analysis pipelines

Multiple 2024–2026 filings embed machine learning directly into single-cell workflows. GIST’s neural network cell-type classifier (KR, 2026) automatically determines cell types and identifies similar single cells via coordinate-space visualization. Shanghai Jiao Tong University’s ODE-based trajectory inference with expectation-maximization optimization (CN, 2026) simultaneously reconstructs RNA velocity fields, pseudotime trajectories, and gene regulatory interaction matrices from scRNA-seq data. Baitu Biosciences applies clustering-based Nanopore barcode demultiplexing without pre-trained deep learning models (CN, 2022), addressing generalizability limitations in existing barcode demultiplexing tools. The trend, as noted in Nature‘s coverage of computational biology, is toward algorithm-native platforms rather than post-hoc analysis tools — and patent protection is following that shift.

“Only one filing in this dataset comprehensively addresses Nanopore-based single-cell multi-omics — the competitive landscape for long-read SCS IP remains relatively open compared to short-read workflows.”

4. Immune cell single-cell profiling for adoptive cell therapy

Iovance Biotherapeutics’ 2026 JP filing on monitoring tumor-infiltrating lymphocyte (TIL) clonality and persistence via TCR CDR3 sequencing represents a direct clinical application of single-cell sequencing to cell therapy manufacturing quality control — a new regulatory-adjacent use case. Filings from AbVitro, iRepertoire, and Maihe Biotechnology converge on the same clinical question: what is the functional state of the immune cell bearing a specific receptor sequence? This niche sits at the intersection of cell therapy, autoimmunity, and vaccine development, and is attracting both US and CN IP activity. Standards bodies including ISO are increasingly engaged in defining quality frameworks for cell and gene therapy manufacturing — a regulatory context that amplifies the strategic value of IP in this niche.

5. Multi-platform compatibility and democratization

Several filings explicitly address interoperability between the 10x Genomics platform and competing systems. Beijing Quanpu Medical Laboratory’s 2023 CN filing describes a collection and mRNA capture workflow compatible with both 10x Genomics and MGI sequencing platforms. Maihe Biotechnology’s 2023 CN filing similarly addresses the MGI/DNBSEQ ecosystem. This signals competitive pressure to reduce platform lock-in and lower per-cell sequencing costs — and suggests that IP protecting platform-agnostic collection, barcoding, and library preparation workflows may command broader licensing value than platform-specific innovations. For IP strategy teams, the PatSnap Insights blog provides ongoing analysis of platform-agnostic IP trends across genomics.